Malignant solid neoplasm, EGFR-mutated
Jump to navigation
Jump to search
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Hainsworth et al. 2018 (MyPathway) | 2014-2016 | Phase 2a, <20 pts in this arm |
Biomarker eligibility criteria
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141